Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBM AGILE Global Adaptive Trial (Austria, Regorafenib arm)
2020-002250-24Phase 2Completed
- Sponsor
- Global Coalition for Adaptive Research
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in glioblastoma (GBM) comparing Regorafenib arm with Control/standard-of-care arm (2 arms). Primary endpoint: Overall survival. Started May 2021; status: completed.
02
Drugs
regorafenib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2020-002250-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002250-24.